← Human Trials & Peer-Reviewed Studies
Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases
Plain-language guide to PMID 29451701 (2018): clinical trial, phase ii study of Somatostatin and Pasireotide.
Key Facts
- PMID
- 29451701
- Journal
- Cancer
- Year
- 2018
- Study type
- Clinical Trial, Phase II
- Authors
- Kim HS et al. (10 authors)
- DOI
- 10.1002/cncr.31192
What This Study Did, in Plain Language
What Was Tested
Researchers studied Somatostatin and Pasireotide in this clinical trial, phase ii publication.
The Norfolk Quality of Life-Neuroendocrine Tumor Questionnaire was used to assess the quality of life (QOL).
Why It Was Studied
Neuroendocrine tumors (NETs) metastasize to the liver.
Everolimus and selective internal radioembolization (SIRT) are approved treatments.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
Eligibility criteria included well or moderately differentiated NETs, bilobar liver metastases, and progression on long-acting octreotide.
Toxicities and responses were evaluated with the Common Terminology Criteria for Adverse Events and the Response Evaluation Criteria in Solid Tumors (version 1.1).
How the Study Was Run
Correlative markers-angiopoietin 1, angiopoietin 2, basic fibroblast growth factor, collagen V, insulin-like growth factor binding protein 1, insulin-like growth factor binding protein 1, interleukin 8, M30, M65, placenta growth factor, and vascular endothelial growth factor receptor 2-were assessed.
What Was Measured
This study evaluated the safety of pasireotide, everolimus, and SIRT.
The subject headings attached to it are Antineoplastic Combined Chemotherapy Protocols, Brachytherapy, Chemoradiotherapy, Embolization, Therapeutic, Everolimus, Kaplan-Meier Estimate and Liver.
Author keywords: liver metastasis, pasireotide, phase 1b, selective internal radioembolization (SIRT) and unresectable neuroendocrine tumor.
What This Means in Plain Language
This is a clinical trial, phase ii of Somatostatin and Pasireotide.
The abstract goes on to report its results in about 12 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (Cancer), a journal based in United States.
More context: the Somatostatin compound page and the Pasireotide compound page, all human trials.
Our Notes on the Compounds
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Pasireotide: An FDA-approved multi-receptor somatostatin analog for Cushing's disease and acromegaly; high blood sugar is a common side effect.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.